Rezolute, Inc.
RZLTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Rezolute, Inc. (RZLT) is listed under Biotechnology. With a market capitalization of $443.9M, it sits in small-cap territory. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
Market Cap
$443.9M
Beta
0.55
P/E (TTM)
—
P/E (Fwd)
-7.36
EPS (TTM)
$-0.85
EPS (Fwd)
$-0.63
ROE
-81.7%
ROA
-48.7%
Cash
$120.3M
Total Debt
$1.1M
Free CF
-$43.7M
52W Change
-14.5%
Annual Financials
Cash vs Debt
With $120.3M in cash and $1.1M in debt, RZLT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$43.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -81.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.55 suggests RZLT is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Rezolute, Inc.'s trajectory.